Ci Investments Inc. Editas Medicine, Inc. Transaction History

Ci Investments Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$7.03 - $11.07 $63 - $99	9 Added 0.08%	11,222 $83,000
Q4 2023 Feb 12, 2024	BUY	$6.25 - $11.11 $3,393 - $6,032	543 Added 5.09%	11,213 $114,000
Q3 2023 Nov 13, 2023	SELL	$6.92 - $9.31 $2,200 - $2,960	-318 Reduced 2.89%	10,670 $83,000
Q2 2023 Aug 11, 2023	BUY	$6.36 - $11.47 $12,147 - $21,907	1,910 Added 21.04%	10,988 $90,000
Q1 2023 May 12, 2023	SELL	$7.03 - $11.53 $822 - $1,349	-117 Reduced 1.27%	9,078 $66,000
Q4 2022 Feb 10, 2023	BUY	$8.32 - $13.21 $63,756 - $101,228	7,663 Added 500.2%	9,195 $82,000
Q3 2022 Nov 14, 2022	SELL	$12.16 - $19.42 $1,386 - $2,213	-114 Reduced 6.93%	1,532 $19,000
Q2 2022 Aug 12, 2022	BUY	$9.99 - $21.35 $8,321 - $17,784	833 Added 102.46%	1,646 $19,000
Q1 2022 May 12, 2022	BUY	$14.08 - $27.63 $11,447 - $22,463	813 New	813 $15,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Ci Investments Inc., based on Form 13F filings with the SEC.

Stay updated on Ci Investments Inc. with notifications on news.